Describing the Value of ctDNA in Clinical Practice

Opinion
Video

The key opinion leaders share their approaches for communicating about circulating tumor DNA and minimal residual disease to patients, emphasizing the significance of ctDNA testing in detecting MRD.

  1. Mackenzie Phillips: How do you describe ctDNA and MRD to patients?
  2. Jing Yi: Why do you think it’s important to do ctDNA testing for MRD?
Recent Videos
Vinay K. Puduvalli, MD, is featured in this series.
9 Experts are featured in this series.
2 experts are featured in this series.
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
9 Experts are featured in this series.
Related Content
For patients with KRAS-mutated colorectal cancer, onvansertib plus FOLFIRI/bevacizumab was effective in those who had not received prior bevacizumab.

Onvansertib Combo Shows Significant Efficacy in KRAS+ Colorectal Cancer

Tim Cortese
November 26th 2024
Article

For patients with KRAS-mutated colorectal cancer, onvansertib plus FOLFIRI/bevacizumab was effective in those who had not received prior bevacizumab.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval

Jagoda Misniakiewicz, PharmD
June 10th 2024
Podcast

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

The resubmission included an analysis of the phase 3 CARES-310 study, which reported favorable overall survival with the combination therapy in uHCC.

FDA Accepts NDA Resubmission of Rivoceranib/Camrelizumab in uHCC

Roman Fabbricatore
October 23rd 2024
Article

The resubmission included an analysis of the phase 3 CARES-310 study, which reported favorable overall survival with the combination therapy in uHCC.

Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.

Ensuring Quality Rectal Cancer Surgery at NAPRC-Accredited Institutions

Steven Wexner, MD, PhD;Arielle Kanters, MD
May 27th 2024
Podcast

Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.

Results from the INNATE trial showed the use of sotigalimab to be a safe and efficacious regimen for patients with rectal cancer.

Neoadjuvant Sotigalimab Proves Efficacious in Rectal Cancer

Ariana Pelosci
October 3rd 2024
Article

Results from the INNATE trial showed the use of sotigalimab to be a safe and efficacious regimen for patients with rectal cancer.

The fixed-dose combination of favezelimab and pembrolizumab did not show an improvement in overall survival compared with the standard of care in patients with metastatic CRC.

Phase 3 KEYFORM-007 Misses Primary End Point in MSS mCRC

Harrison Widelitz
September 25th 2024
Article

The fixed-dose combination of favezelimab and pembrolizumab did not show an improvement in overall survival compared with the standard of care in patients with metastatic CRC.